{
    "clinical_study": {
        "@rank": "132982", 
        "arm_group": [
            {
                "arm_group_label": "Run-in - Aerobic - Resistance", 
                "arm_group_type": "Experimental", 
                "description": "Week -12 to 0: Run-in period with no training\nWeek 0 to 12: Aerobic training on ergometer bicycle\nWeek 12 to 24: Resistance training with dumbbells"
            }, 
            {
                "arm_group_label": "Run-in - Resistance - Aerobic", 
                "arm_group_type": "Experimental", 
                "description": "Week -12 to 0: Run-in period with no training\nWeek 0 to 12: Resistance training with dumbbells\nWeek 12 to 24: Aerobic training on ergometer bicycle"
            }
        ], 
        "brief_summary": {
            "textblock": "Resistance and aerobic exercise has been shown to be effective for maintenance of muscle\n      strength in patients with neuromuscular diseases.\n\n      Exercise in CIDP and MMN is sparsely described. The aim of the study is to evaluate changes\n      in muscle strength during high intensive resistance training and changes in maximal oxygen\n      consumption (VO2-max) during high intensive aerobic training in patients with CIDP or MMN in\n      maintenance therapy with subcutaneous immunoglobulin.\n\n      The hypotheses are that muscle strength and VO2-max are significantly increased during the\n      training sessions."
        }, 
        "brief_title": "Effect of Resistance and Aerobic Exercise in CIDP or MMN", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Inflammatory Demyelinating Polyneuropathy", 
            "Multifocal Motor Neuropathy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Polyneuropathies", 
                "Neuritis", 
                "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age > 18 and < 80 years\n\n          -  Diagnosed with definite or probable CIDP or definite or probable MMN fulfilling the\n             European Federation of Neurological Sciences/Peripheral Nerve Society (EFNS/PNS)\n             criteria\n\n          -  Stable maintenance therapy with immunoglobulin (no change of dosage < 3 months before\n             inclusion)\n\n          -  Duration of CIDP or MMN > 6 months\n\n          -  Negative result on a pregnancy test (HCG-based assay in urine) for women of\n             childbearing potential and use of a reliable method of contraception for the duration\n             of the study\n\n        Exclusion Criteria:\n\n          -  Other cause of neuropathy (incl. pressure neuropathy)\n\n          -  Exercise before enrolment (> 1 hour of exercise per week or > 4 km bicycling per day)\n\n          -  Walking distance < 10 meter with or without aid\n\n          -  Diabetes mellitus, severe cardiac or pulmonary disease, malignancies\n\n          -  Known history of adverse reactions to Immunoglobulin A in other products\n\n          -  Ongoing history of hypersensitivity or persistent reactions to blood or plasma\n             derived products.\n\n          -  History of malignancies of lymphoid cells and immunodeficiency with lymphoma\n\n          -  Known liver function impairment (ALAT 3 times above upper limit of normal)\n\n          -  Known protein-losing enteropathies or proteinuria.\n\n          -  Known of renal function impairment (creatinine >120 micromol/L or creatinine >1.35\n             mg/dL), or predisposition for acute renal failure (e.g., any degree of pre-existing\n             renal insufficiency or routine treatment with known nephritic drugs).\n\n          -  Treatment with any investigational medicinal product within 3 months prior to first\n             infusion of Gammanorm\n\n          -  Known or suspected HIV, Hepatitis Virus C or B infection\n\n          -  Pregnant or nursing women\n\n          -  Planned pregnancy during course of the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02121678", 
            "org_study_id": "2013-200"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Run-in - Aerobic - Resistance", 
                    "Run-in - Resistance - Aerobic"
                ], 
                "description": "Participants do resistance training of selected muscle groups. Resistance are predefined from 1-repetition max (1-RM) and increased during the 12 weeks of training:\nWeek 0-4: 70-80 % of 1-RM\nWeek 5-8: 75-86 % of 1-RM\nWeek 9-12: 80-92% of 1-RM\nParticipants trains unilateral, the opposite site serves as reference.\nMMN patients train elbow (flexion/extension) and wrist (flexion/extension)\nCIDP patients train knee (flexion/extension) and elbow (flexion/extension)", 
                "intervention_name": "Resistance training", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Run-in - Aerobic - Resistance", 
                    "Run-in - Resistance - Aerobic"
                ], 
                "description": "Participants train on ergometer bicycle 2 times weekly increasing during the first weeks to 3 times weekly. Workload is measured before initiation and VO2-max, heart rate and blood pressure will be measured as well.\nPatients train with 60-75 % of VO2-max for 30 minutes per training session. They use heart rate monitor to store data.", 
                "intervention_name": "Aerobic training", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Immunoglobulins", 
                "Antibodies"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Resistance training", 
            "Aerobic exercise", 
            "Isokinetic muscle strength", 
            "Bicycle ergometry test", 
            "Subcutaneous immunoglobulin"
        ], 
        "lastchanged_date": "April 22, 2014", 
        "location": [
            {
                "contact": {
                    "email": "hennande@rm.dk", 
                    "last_name": "Henning Andersen, DMSc"
                }, 
                "contact_backup": {
                    "email": "larsmark@rm.dk", 
                    "last_name": "Lars Markvardsen, MD", 
                    "phone": "+45 7846 3337"
                }, 
                "facility": {
                    "address": {
                        "city": "Aarhus C", 
                        "country": "Denmark", 
                        "zip": "8000"
                    }, 
                    "name": "Department of Neurology, Aarhus University Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Lars Markvardsen, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Henning Andersen, DMSc", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "ingelise.christiansen@regionh.dk", 
                    "last_name": "Ingelise Christiansen, PhD"
                }, 
                "contact_backup": {
                    "email": "karen.brorup.heje.pedersen.02@regionh.dk", 
                    "last_name": "Karen Heje Pedersen"
                }, 
                "facility": {
                    "address": {
                        "city": "Copenhagen", 
                        "country": "Denmark", 
                        "zip": "2100"
                    }, 
                    "name": "Department of Neurology, Rigshospitalet, Copenhagen University Hospital"
                }, 
                "investigator": {
                    "last_name": "Ingelise Christiansen, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Resistance and Aerobic Exercise on Muscle Strength, Aerobic Capacity and Quality of Life in Patients Treated With Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or Multifocal Motor Neuropathy (MMN)", 
        "overall_contact": {
            "email": "hennande@rm.dk", 
            "last_name": "Henning Andersen, DMSc", 
            "phone": "+45 7846 3281"
        }, 
        "overall_contact_backup": {
            "email": "larsmark@rm.dk", 
            "last_name": "Lars H Markvardsen, MD", 
            "phone": "+45 7846 3337"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Denmark: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Changes in isokinetic muscle strength during resistance exercise. Four muscle groups bilateral are selected.\nCIDP: Knee flexion/extension Elbow flexion/extension MMN: Elbow flexion/extension Wrist flexion/extension", 
                "measure": "Changes in isokinetic muscle strength", 
                "safety_issue": "No", 
                "time_frame": "-12, 0, 6, 12 weeks or -12, 0, 12, 18, 24 weeks"
            }, 
            {
                "description": "VO2-max are measured during the 12 weeks aerobic exercise session and at enrolment 12 weeks before start of exercise.\nVO2-max are measured while the participant running on a ergometer bicycle by accumulation of exhaled air", 
                "measure": "Changes in maximal oxygen consumption (VO2-max)", 
                "safety_issue": "No", 
                "time_frame": "-12, 0, 6, 12 weeks or -12, 0, 12, 18, 24 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02121678"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in Medical Research Council (MRC)", 
                "safety_issue": "No", 
                "time_frame": "-12, 0, 6, 12, 18, 24 weeks"
            }, 
            {
                "measure": "Change in Overall Disability Sum Score (ODSS)", 
                "safety_issue": "No", 
                "time_frame": "-12, 0, 6, 12, 18, 24 weeks"
            }, 
            {
                "measure": "Change in 6-Minute Walk test", 
                "safety_issue": "No", 
                "time_frame": "-12, 0, 6, 12 weeks or -12, 0, 12, 18, 24 weeks"
            }, 
            {
                "measure": "Change in Quality of Life measured by The Short Form (36) Health Survey (SF-36) questionnaire", 
                "safety_issue": "No", 
                "time_frame": "-12, 0, 6, 12, 18, 24 weeks"
            }, 
            {
                "measure": "Change in Fatigue Severity Score (FSS)", 
                "safety_issue": "No", 
                "time_frame": "-12, 0, 6, 12, 18, 24 weeks"
            }
        ], 
        "source": "University of Aarhus", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Aarhus", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}